David Lacomis

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1747506/publications.pdf

Version: 2024-02-01

85	3,336	218677	161849
papers	citations	26 h-index	54 g-index

89	89	89	4166
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Role of Intravenous Immunoglobulin in Necrotizing Autoimmune Myopathy. Journal of Clinical Rheumatology, 2022, 28, e517-e520.	0.9	8
2	Perceived utility of electrodiagnostic testing in critical illness myopathy and polyneuropathy: A survey of intensive care unit providers. Muscle and Nerve, 2022, , .	2.2	0
3	Lambertâ€“Eaton Myasthenic Syndrome and Dermatomyositis With Antiâ€“TIF1-gamma Autoantibody: A Unique Association of Autoimmune Neuromuscular Conditions Without Malignancy. Journal of Clinical Neuromuscular Disease, 2021, 22, 164-168.	0.7	2
4	What Is in the Neuromuscular Junction Literature?. Journal of Clinical Neuromuscular Disease, 2021, 22, 147-154.	0.7	1
5	SDH Subunit C Regulates Muscle Oxygen Consumption and Fatigability in an Animal Model of Pulmonary Emphysema. American Journal of Respiratory Cell and Molecular Biology, 2021, 65, 259-271.	2.9	9
6	Neuronal mitochondrial dysfunction in sporadic amyotrophic lateral sclerosis is developmentally regulated. Scientific Reports, 2021, 11, 18916.	3.3	19
7	Effects of mexiletine on hyperexcitability in sporadic amyotrophic lateral sclerosis: Preliminary findings from a small phase II randomized controlled trial. Muscle and Nerve, 2021, 63, 371-383.	2.2	13
8	What Is in the Myopathy Literature?. Journal of Clinical Neuromuscular Disease, 2021, 23, 66-74.	0.7	0
9	Granulomatous Myositis Associated With Acetylcholine Receptor Antibodies Without Clinical Myasthenia. Journal of Clinical Neuromuscular Disease, 2021, 23, 49-52.	0.7	0
10	IL-13-driven pulmonary emphysema leads to skeletal muscle dysfunction attenuated by endurance exercise. Journal of Applied Physiology, 2020, 128, 134-148.	2.5	18
11	Late-onset peripheral neuropathy in patients with wild type transthyretin amyloidosis (wtATTR). Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 142-143.	3.0	8
12	Longitudinal biomarkers in amyotrophic lateral sclerosis. Annals of Clinical and Translational Neurology, 2020, 7, 1103-1116.	3.7	62
13	What's in the Neuromuscular Junction Literature?. Journal of Clinical Neuromuscular Disease, 2020, 21, 195-204.	0.7	2
14	Making the Diagnosis of Myositis: Electrodiagnostic Testing. , 2020, , 99-108.		0
15	Making the Diagnosis of Myositis: Muscle Biopsy and Interpretation. , 2020, , 109-124.		0
16	What is in the Myopathy Literature?. Journal of Clinical Neuromuscular Disease, 2020, 22, 77-83.	0.7	2
17	MYL2-associated congenital fiber-type disproportion and cardiomyopathy with variants in additional neuromuscular disease genes; the dilemma of panel testing. Journal of Physical Education and Sports Management, 2019, 5, a004184.	1.2	5
18	Differential tractography as a track-based biomarker for neuronal injury. NeuroImage, 2019, 202, 116131.	4.2	66

#	Article	IF	Citations
19	What is in the Myopathy Literature?. Journal of Clinical Neuromuscular Disease, 2019, 21, 7-13.	0.7	0
20	Upper motor neuron assessment and early diagnosis in ALS. Neurology, 2019, 92, 255-256.	1.1	4
21	Clinical spectrum of neuromuscular complications after immune checkpoint inhibition. Neuromuscular Disorders, 2019, 29, 127-133.	0.6	42
22	What is in the Myopathy Literature?. Journal of Clinical Neuromuscular Disease, 2018, 19, 131-134.	0.7	0
23	Duchenne muscular dystrophy caused by a novel deep intronic DMD mutation. Muscle and Nerve, 2018, 57, E136-E138.	2.2	5
24	Electrodiagnostic studies in the intensive care unit: A comparison study 2 decades later. Muscle and Nerve, 2018, 57, 772-776.	2.2	5
25	Lambertâ€“Eaton myasthenic syndrome: mouse passiveâ€transfer model illuminates disease pathology and facilitates testing therapeutic leads. Annals of the New York Academy of Sciences, 2018, 1412, 73-81.	3.8	14
26	What is in the Neuromuscular Junction Literature?. Journal of Clinical Neuromuscular Disease, 2018, 20, 76-84.	0.7	1
27	Reported direct aminopyridine effects on voltage-gated calcium channels is a high-dose pharmacological off-target effect of no clinical relevance. Journal of Biological Chemistry, 2018, 293, 16100.	3.4	4
28	What is in the Myopathy Literature?. Journal of Clinical Neuromuscular Disease, 2018, 19, 217-223.	0.7	0
29	What's in the Literature?. Journal of Clinical Neuromuscular Disease, 2017, 18, 165-175.	0.7	0
30	Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72 -associated amyotrophic lateral sclerosis. Science Translational Medicine, 2017, 9, .	12.4	179
31	TIA1 Mutations in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Promote Phase Separation and Alter Stress Granule Dynamics. Neuron, 2017, 95, 808-816.e9.	8.1	493
32	Clinical and neuropathological features of ALS/FTD with TIA1 mutations. Acta Neuropathologica Communications, 2017, 5, 96.	5.2	38
33	Proximal Limb Weakness in a Patient with Celiac Disease: Copper Deficiency, Gluten Sensitivity, or Both as the Underlying Cause?. Case Reports in Neurological Medicine, 2016, 2016, 1-4.	0.4	3
34	Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine. Muscle and Nerve, 2016, 53, 165-168.	2.2	24
35	Receptor for Advanced Glycation End Products and its Inflammatory Ligands are Upregulated in Amyotrophic Lateral Sclerosis. Frontiers in Cellular Neuroscience, 2015, 9, 485.	3.7	55
36	Exposure to hazardous air pollutants and the risk of amyotrophic lateral sclerosis. Environmental Pollution, 2015, 197, 181-186.	7.5	64

#	Article	IF	Citations
37	Letter to the editor on â€œExposure to hazardous air pollutants and the risk of amyotrophic lateral sclerosisâ€• Environmental Pollution, 2015, 207, 432-433.	7.5	0
38	Use of diffusion spectrum imaging in preliminary longitudinal evaluation of amyotrophic lateral sclerosis: development of an imaging biomarker. Frontiers in Human Neuroscience, 2014, 8, 270.	2.0	25
39	Life factors affecting depression and burden in amyotrophic lateral sclerosis caregivers. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2014, 15, 292-297.	1.7	39
40	Complete reversal of Lambertâ€“Eaton myasthenic syndrome synaptic impairment by the combined use of a K⁺ channel blocker and a Ca²⁺ channel agonist. Journal of Physiology, 2014, 592, 3687-3696.	2.9	24
41	Environmental and Occupational Risk Factors for Amyotrophic Lateral Sclerosis: A Case-Control Study. Neurodegenerative Diseases, 2014, 14, 31-38.	1.4	59
42	Advanced diffusion MRI fiber tracking in neurosurgical and neurodegenerative disorders and neuroanatomical studies: A review. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 2286-2297.	3.8	93
43	Localized scleroderma and regional inflammatory myopathy. Neuromuscular Disorders, 2014, 24, 425-430.	0.6	8
44	Acute Neuromuscular Weakness in the Intensive Care Unit. , 2014, , 1515-1532.		0
45	Electrophysiology of neuromuscular disorders in critical illness. Muscle and Nerve, 2013, 47, 452-463.	2.2	76
46	What's in the Literature?. Journal of Clinical Neuromuscular Disease, 2013, 15, 34-42.	0.7	0
47	Electrodiagnostic Approach to the Patient with Suspected Myopathy. Neurologic Clinics, 2012, 30, 641-660.	1.8	21
48	Neurosarcoidosis. Current Neuropharmacology, 2011, 9, 429-436.	2.9	113
49	Neuromuscular Disorders in Critically Ill Patients: Review and Update. Journal of Clinical Neuromuscular Disease, 2011, 12, 197-218.	0.7	47
50	Postâ€translational protein modifications of transthyretin in amyotrophic lateral sclerosis. FASEB Journal, 2010, 24, 568.10.	0.5	0
51	Cystatin C: expression and activity in amyotrophic lateral sclerosis. FASEB Journal, 2010, 24, 568.11.	0.5	0
52	Severe hydroxychloroquine myopathy. Muscle and Nerve, 2008, 38, 1206-1210.	2.2	64
53	Neuromuscular Pathology Case. Journal of Clinical Neuromuscular Disease, 2008, 10, 79-82.	0.7	2
54	Biomarkers for ALS disease progression. FASEB Journal, 2008, 22, 173.6.	0.5	0

#	Article	IF	Citations
55	Cystatin C: A potential surrogate biomarker in amyotrophic lateral sclerosis. FASEB Journal, 2008, 22, 173.7.	0.5	0
56	Approach to Vasculitic Neuropathies. Journal of Clinical Neuromuscular Disease, 2007, 9, 265-276.	0.7	31
57	Neuromuscular Pathology Unknown. Journal of Clinical Neuromuscular Disease, 2005, 6, 191-192.	0.7	0
58	Myasthenic Crisis. Neurocritical Care, 2005, 3, 189-194.	2.4	66
59	Neuropathy and Fabry's disease. Muscle and Nerve, 2005, 31, 102-107.	2.2	31
60	Clinical utility of peripheral nerve biopsy. Current Neurology and Neuroscience Reports, 2005, 5, 41-47.	4.2	10
61	The utility of muscle biopsy. Current Neurology and Neuroscience Reports, 2004, 4, 81-86.	4.2	13
62	Evaluation of the Patient With Foot Pain. Journal of Clinical Neuromuscular Disease, 2004, 6, 24-39.	0.7	3
63	Hypothyroid Myopathy. Journal of Clinical Neuromuscular Disease, 2002, 4, 100-101.	0.7	1
64	Electrodiagnostic approach to the patient with suspected myopathy. Neurologic Clinics, 2002, 20, 587-603.	1.8	13
65	Smallâ€fiber neuropathy. Muscle and Nerve, 2002, 26, 173-188.	2.2	356
66	Critical illness neuromyopathies. Advances in Neurology, 2002, 88, 325-35.	0.8	4
67	Critical illness myopathy. Muscle and Nerve, 2000, 23, 1785-1788.	2.2	188
68	The use of percutaneous needle muscle biopsy in the diagnosis of myopathy. Current Rheumatology Reports, 2000, 2, 225-229.	4.7	21
69	Giant cell arteritis presenting with proximal weakness and skeletal muscle vasculitis. , 1999, 22, 142-144.		8
70	Comparison of different modalities for detection of small fiber neuropathy. Clinical Neurophysiology, 1999, 110, 1909-1912.	1.5	86
71	Causes of neuromuscular weakness in the intensive care unit: A study of ninety-two patients. , 1998, 21, 610-617.		177
72	Oculopharyngeal muscular dystrophy: Non-French-Canadian pedigrees. , 1998, 21, 816-818.		6

#	Article	IF	Citations
73	Mononeuropathies associated with liver transplantation. , 1998, 21, 896-901.		23
74	Neuropathy Associated with Hyperoxaluria: Improvement After Combined Renal and Liver Transplantations. Brain Pathology, 1998, 8, 247-251.	4.1	12
75	October 1996 â€" Rapidly Progressive Weakness. Brain Pathology, 1997, 7, 837-838.	4.1	0
76	Small fiber neuropathy and vasculitis. Arthritis and Rheumatism, 1997, 40, 1173-1177.	6.7	49
77	Percutaneous needle muscle biopsy in the evaluation of patients with suspected inflammatory myopathy. Arthritis and Rheumatism, 1997, 40, 1886-1891.	6.7	28
78	Vacuolar myopathies in adults with myalgias: Value of paraspinal muscle investigation. , 1997, 20, 1321-1323.		4
79	CASE OF THE MONTH June 1996 - Anorexia Nervosa. Brain Pathology, 1996, 6, 535-536.	4.1	10
80	Acute myopathy of intensive care: Clinical, electromyographic, and pathological aspects. Annals of Neurology, 1996, 40, 645-654.	5.3	266
81	Mushroom myopathy. , 1996, 19, 790-792.		8
82	Case of the month. Disseminated histoplasmosis presenting as myositis and fasciitis in a patient with dermatomyositis. Muscle and Nerve, 1995, 18, 531-535.	2.2	26
83	A reversible paralytic syndrome with anti-GD1b Antibodies following influenza immunization. Muscle and Nerve, 1995, 18, 1199-1201.	2.2	7
84	Critically ill patient with newly acquired weakness: The clinicopathological spectrum. Annals of Neurology, 1994, 35, 257-259.	5.3	50
85	Acute myopathy and neuropathy in status asthmaticus: Case report and literature review. Muscle and Nerve, 1993, 16, 84-90.	2.2	122